What is clonal
hematopoiesis?

Hematopoiesis is maintained by a population of stem and progenitor cells that continuously generates blood cells. Over time, individual hematopoietic cells may acquire somatic genetic changes. These changes are acquired during life rather than necessarily inherited through the germline.

Clonal hematopoiesis (CH) occurs when descendants of a hematopoietic cell expand to contribute a detectable share of blood-cell production. Some clones arise because mutations change cellular fitness, while environmental influences and aging also shape clonal competition.

A common form, clonal hematopoiesis of indeterminate potential (CHIP), refers to the presence of qualifying somatic mutations associated with myeloid neoplasia in individuals without an established hematologic neoplasm or unexplained cytopenias attributable to a clonal condition. A variant allele fraction of at least 2% is a conventional diagnostic threshold.

Why clonal expansion
increases with age.

The hematopoietic system experiences repeated cell division, environmental stress and exposure to inflammatory signals throughout life. Somatic mutations accumulate in some hematopoietic cells, while selection can favor clones possessing particular functional advantages.

A landmark study published in 2014 demonstrated that detectable clonal mutations in peripheral blood became substantially more common with increasing age. In that cohort, mutations in selected cancer-associated genes were detected in approximately 5.6% of people aged 60–69 and 9.5% aged 70–79.

These frequencies depend heavily on the sequencing strategy, depth, gene selection and minimum detectable clone size. Modern high-sensitivity methods can detect smaller clones, so prevalence estimates are not interchangeable between studies.

Aging-related clonal expansion is therefore not simply the appearance of mutations. It reflects the interaction between mutation acquisition, cellular competition and the changing hematopoietic environment.

The genes that
shape clonal fitness.

The genes most frequently affected in CHIP include DNMT3A, TET2 and ASXL1. These genes participate in epigenetic or chromatin-related regulation. Mutations can alter gene-expression programs and influence how hematopoietic cells compete, self-renew or differentiate.

Other recurrent alterations affect signaling, RNA splicing, DNA damage responses or transcriptional regulation. Examples include JAK2, SF3B1, SRSF2, TP53 and PPM1D. Their biological effects are not interchangeable. Some mutations show stronger associations with particular clinical outcomes than others.

A mutation in one of these genes does not automatically imply a clonal advantage in every setting. Specific sequence variants, co-occurring mutations and environmental selection can strongly influence biological behavior.

CHIP, CCUS and
hematologic malignancy.

The discovery of recurrent somatic mutations in otherwise healthy people created a need for more precise terminology. Clonal hematopoiesis can occur in individuals who have no obvious blood count abnormalities and no diagnosed hematologic cancer.

CHIP traditionally applies when qualifying mutations are present at a variant allele fraction of at least 2%, with no accompanying unexplained cytopenias or established hematologic neoplasm. When persistent unexplained cytopenia coexists with evidence of myeloid clonality but diagnostic criteria for an overt neoplasm are not met, the term clonal cytopenia of undetermined significance (CCUS) may apply.

By contrast, myelodysplastic neoplasms and acute myeloid leukemia require additional defined clinical, morphological, genetic or laboratory criteria. Molecular findings must be interpreted within the full diagnostic context.

Variant allele fraction:
measuring a clone.

One common measurement in clonal hematopoiesis research is variant allele fraction (VAF). It describes the proportion of sequencing reads at a genomic position that carry a particular variant. VAF can provide information about the representation of a clone in a sampled cell population.

For a heterozygous autosomal mutation in a diploid region without copy-number changes, a VAF of 10% might correspond roughly to 20% of cells carrying that mutation. However, this simplified relationship is not universal.

Copy-number variation, loss of heterozygosity, multiple clones, cell composition and technical sequencing factors can change interpretation. A rising VAF across serial samples may indicate expansion, but differences in sample type and methodology must be considered.

Does a clone
become leukemia?

Clonal hematopoiesis is associated with increased future risk of selected hematologic malignancies. Large observational studies identified this relationship in people carrying acquired mutations without a previously diagnosed blood cancer.

Importantly, a higher relative risk does not mean most people with CHIP will develop leukemia. The absolute rate of progression is generally low for many CHIP carriers, and risk varies according to mutation identity, number of variants, clone size, blood counts and other factors.

Some patterns of mutation are associated with higher progression risk than others, particularly in the setting of persistent cytopenias or additional disease- associated abnormalities. Clinical evaluation uses more than sequencing data alone.

Why CHIP matters
beyond blood cancer.

An important discovery in clonal hematopoiesis research is its association with cardiovascular disease. In a 2017 study, CHIP was associated with increased risk of atherosclerotic coronary events. Experimental work suggested that some mutation-bearing immune cells may contribute to vascular inflammation.

Myeloid descendants of clonal stem cells can include monocytes and macrophages. Certain mutations, notably those involving TET2, have been investigated for their effects on inflammatory signaling. Animal studies provide mechanistic support for a contribution to atherosclerosis, though effects differ by mutation and disease context.

More recent research also examines CHIP associations with heart failure and other cardiovascular conditions. These findings do not mean that every CHIP carrier develops cardiovascular disease or that one uniform mechanism applies to all mutations.

The connection between stem cells, immune signaling and cardiovascular disease illustrates how hematopoiesis influences tissues far beyond the bone marrow.

How scientists
identify clones.

Detecting clonal hematopoiesis commonly involves DNA sequencing of blood or marrow samples. Targeted panels can examine genes recurrently altered in hematologic disease, while broader sequencing approaches can capture additional genomic variation.

Analytical workflows must distinguish genuine low-frequency variants from sequencing artifacts, inherited variation and technically ambiguous findings. Sequencing depth, molecular error correction, variant calling and validation approaches all influence sensitivity and reliability.

Single-cell genotyping and combined molecular profiling can investigate which mutations coexist within individual clones. Longitudinal sampling allows researchers to study how clonal representation changes across time.

For more on the experimental techniques used to characterize hematopoietic cells, explore Research Methods and our article on single-cell RNA sequencing .

What a CHIP finding
does not tell us.

Although a CHIP result can identify an expanded mutation-bearing blood-cell population, it cannot alone establish leukemia, determine the future clinical course or explain every abnormal blood count.

Risk interpretation depends on mutation characteristics, the size and number of clones, blood-cell measurements, individual medical history and other relevant evidence. No universally applicable management strategy can be inferred from a sequencing result without this context.

Observational associations between CHIP and disease also require careful interpretation. Population-level risk estimates do not predict an individual outcome with certainty, and the evidence supporting specific clinical interventions continues to evolve.

From clonal evolution
to biotechnology.

Clonal hematopoiesis research connects fundamental stem cell biology with genome sequencing, population genetics, immunology and the development of new experimental technologies. It provides a natural system for studying how somatic mutations influence cell competition over decades.

Modern tools include deep sequencing, single-cell genotyping, computational phylogenetics, functional gene editing and experimental models of hematopoietic differentiation. These approaches can help identify molecular mechanisms of clonal selection and investigate how mutation-bearing cells influence tissue inflammation.

Emerging work explores whether specific inflammatory pathways or other mechanisms could eventually be targeted in defined CHIP-associated conditions. These are active research questions, and optimal preventive or therapeutic strategies remain incompletely established.

The broader scientific lesson is that hematopoiesis is not genetically static. The stem cell population changes with age, environmental pressure and acquired mutations. Some changes remain compatible with normal blood counts, while others can contribute to disease.

Understanding this diversity creates opportunities for improved biological models, more precise research measurements and better-informed future approaches to hematologic and inflammatory disorders.